Lepu Biopharma (SEHK:2157) Profit Swing To C¥41.7m Tests Bearish Earnings Narratives

Simply Wall St.03-26 19:15

Lepu Biopharma (SEHK:2157) has just posted its FY 2025 numbers with first half revenue of C¥465.9 million and basic EPS of C¥0.024, while the trailing twelve months show revenue of C¥934.9 million and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622868011?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-26 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622868011","market":"hk","top_or_hot":-1,"title":"Lepu Biopharma (SEHK:2157) Profit Swing To C¥41.7m Tests Bearish Earnings Narratives","media":"Simply Wall St.","content":"<div>\n<p>Lepu Biopharma (SEHK:2157) has just posted its FY 2025 numbers with first half revenue of C¥465.9 million and basic EPS of C¥0.024, while the trailing twelve months show revenue of C¥934.9 million and...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-profit-swing-to-c417m-tests-bearish\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lepu Biopharma (SEHK:2157) Profit Swing To C¥41.7m Tests Bearish Earnings Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLepu Biopharma (SEHK:2157) Profit Swing To C¥41.7m Tests Bearish Earnings Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-profit-swing-to-c417m-tests-bearish><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lepu Biopharma (SEHK:2157) has just posted its FY 2025 numbers with first half revenue of C¥465.9 million and basic EPS of C¥0.024, while the trailing twelve months show revenue of C¥934.9 million and...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-profit-swing-to-c417m-tests-bearish\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02157","symbol_name":"乐普生物-B","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-profit-swing-to-c417m-tests-bearish","article_id":"2622868011","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-profit-swing-to-c417m-tests-bearish","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622868011","pubTimestamp":1774523714,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Lepu Biopharma (SEHK:2157) has just posted its FY 2025 numbers with first half revenue of C¥465.9 million and basic EPS of C¥0.024, while the trailing twelve months show revenue of C¥934.9 million and basic EPS of C¥0.15. Over the last few reporting halves, revenue has moved from C¥133.3 million in 1H 2024 to C¥234.5 million in 2H 2024 and then to C¥465.9 million in 1H 2025. Net income has shifted from losses of C¥192.4 million and C¥218.9 million to a profit of C¥41.7 million, pointing to a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"02157":"乐普生物-B","BK1161":"生物科技"},"translate_title":"乐普生物制药(SEHK：2157)利润增至4170万日元考验看跌盈利叙述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":0.9},"content_text":"Lepu Biopharma (SEHK:2157) has just posted its FY 2025 numbers with first half revenue of C¥465.9 million and basic EPS of C¥0.024, while the trailing twelve months show revenue of C¥934.9 million and basic EPS of C¥0.15. Over the last few reporting halves, revenue has moved from C¥133.3 million in 1H 2024 to C¥234.5 million in 2H 2024 and then to C¥465.9 million in 1H 2025. Net income has shifted from losses of C¥192.4 million and C¥218.9 million to a profit of C¥41.7 million, pointing to a period where margins have been rebuilding and are now under close watch as investors consider how durable this earnings profile is. See our full analysis for Lepu Biopharma. With the headline figures on the table, the next step is to set these results against the widely followed narratives around Lepu Biopharma to see which stories align with the data and which may need a rethink. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:2157 Revenue & Expenses Breakdown as at Mar 2026 AdvertisementTTM profit of C¥261.4 million after prior losses  Over the trailing twelve months, Lepu Biopharma reports net income of C¥261.4 million, compared with losses of C¥411.4 million in the earlier 12 month period shown, while basic EPS over the latest trailing period sits at C¥0.15. What stands out for the bullish view is that this recent profitability, together with reported five year earnings growth of 49.3% per year, sits alongside a 1H 2025 profit of C¥41.7 million after two earlier half year losses. This heavily supports the idea of an earnings profile that has already turned positive even though future forecasts still call for an average earnings decline of 98.9% per year.\n     Supporters can point to C¥934.9 million of trailing twelve month revenue against C¥367.8 million in the earlier period shown as evidence that the business is operating at a larger scale than when it was loss making. At the same time, the forecast earnings decline of 98.9% per year directly pushes back on the more optimistic angle by suggesting that the recent C¥261.4 million profit may not reflect the earnings level analysts currently expect to see ahead.    Bulls and skeptics are reading the same profit swing very differently, so it helps to see how others are connecting these figures to their long term story for the stock. 📊 Read the what the Community is saying about Lepu Biopharma. P/E of 31.4x with C¥5.15 share price  At a share price of C¥5.15, Lepu Biopharma trades on a P/E of 31.4x, which sits below the reported Asian biotechs industry average of about 38.5% to 38.9% but above the specific peer group average of 14.9x. Critics who are cautious on the stock point out that paying 31.4x for a company where earnings are forecast to decline on average by 98.9% per year can be hard to justify, and the fact that the multiple is more than double the 14.9x peer average reinforces that concern even though it is still below the broader industry level.\n     This tension between a below industry P/E and a higher than peer P/E means bears can argue that the valuation already embeds a stronger profile than other similar names, even while forecasts show earnings falling rather than rising. Investors who focus on reported profitability might counter that a trailing EPS of C¥0.15 at least provides current earnings to compare with the C¥5.15 price, but the sharp forecast decline keeps the bearish argument very much alive.    Revenue growth forecasts vs earnings drop risk  Revenue is forecast to grow about 13.2% per year over the next three years, even as the same forecasts call for earnings to decline on average by 98.9% per year over that period. What is striking for a cautious, more bearish narrative is that a business expected to grow its top line at roughly a mid teens rate is still projected to see earnings contract very sharply, which suggests that higher sales alone are not expected to translate into higher profits despite the recent move from a C¥411.4 million loss to a C¥261.4 million profit in the trailing figures.\n     For skeptics, this combination of revenue growth and forecast earnings decline raises the possibility that costs, pricing or product mix could offset the benefit of higher sales, even though the precise drivers are not detailed in these numbers. Supporters of the stock, on the other hand, may focus on the C¥934.9 million trailing revenue base as a sign of market traction, but the earnings forecasts make it clear that growth in sales alone does not remove the risk around future profitability.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Lepu Biopharma's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. With a mix of bullish and cautious signals in the recent numbers, it helps to move quickly, review the figures yourself and test whether the current narrative really fits your view. To weigh both sides of the story in one place, start with the 3 key rewards and 1 important warning sign. See What Else Is Out There Lepu Biopharma combines a P/E of 31.4x with forecasts for earnings to fall about 98.9% per year, which puts real pressure on the bullish case. If that kind of rich multiple and earnings risk makes you uneasy, compare it with companies in the 229 high quality undervalued stocks and see how many offer stronger value on steadier foundations.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622868011","isCrawlerRequest":true}